A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Small cell lung cancer (SCLC) is an aggressive neuroendocrine lung cancer with limited therapeutic advancements over the past three decades.
• There is a critical need for effective treatments and improved prognosis for SCLC patients.
• Ser/Arg repetitive matrix 4 (SRRM4) has been identified as a splicing activator abnormally overexpressed in SCLC.

Purpose of the Study:

• To investigate SRRM4 as a potential therapeutic target for SCLC.
• To develop and evaluate a novel gapmer antisense oligonucleotide (gASO) targeting SRRM4.
• To explore the potential of miR-4516 as a diagnostic marker in SCLC.

Main Methods:

• Screening of a gapmer antisense oligonucleotide (gASO) targeting SRRM4 in vitro.
• In vitro validation of gASO efficacy in repressing SRRM4 mRNA and inducing SCLC cell death.
• In vivo testing of the SRRM4-targeted gASO in a lung cancer mouse model.
• Analysis of miRNA microarray to identify circulating microRNAs in SCLC patients' exosomes.

Main Results:

• The developed gASO effectively repressed SRRM4 mRNA and protein synthesis.
• gASO treatment led to significant SCLC cell death in vitro.
• Administration of the SRRM4-targeted gASO resulted in dramatic tumor reduction in a lung cancer mouse model.
• Abnormal elevation of miR-4516 was observed in exosomes from SCLC patients' blood.
• gASO treatment in the mouse model concurrently reduced plasma miR-4516 levels.

Conclusions:

• SRRM4 is a viable therapeutic target for small cell lung cancer.
• An SRRM4-targeted gASO demonstrates significant anti-tumor efficacy in preclinical models.
• A novel miRNA diagnostic methodology involving plasma miR-4516 shows potential for SCLC detection.
• The combination of SRRM4-targeted gASO therapy and miRNA diagnostics represents a promising breakthrough for high-mortality SCLC.